SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust (SLV) is currently experiencing high volatility as investors grapple with complex macroeconomic factors, including shifting inflation data and ongoing geopolitical uncertainties. The community remains deeply divided, with many traders debating whether the current price action represents a temporary correction or a long-term accumulation opportunity for silver’s critical role in AI and industrial sectors.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is experiencing intense volatility driven by conflicting geopolitical news and anticipation ahead of critical economic data releases. Community sentiment is deeply polarized, with traders actively debating whether the aggressive intraday price swings represent a sustainable V-shaped recovery or a manipulative bull trap designed to flush out retail positions.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is experiencing a surge in trading activity driven by a strategic partnership with Aurelia Technologies to advance additive manufacturing for next-gen gas turbines, coupled with bullish sentiment surrounding its critical role as a supplier for the SpaceX ecosystem. Community members are actively discussing the stock's recovery potential, with many highlighting the company's Q1 growth, debt reduction, and strategic positioning in the aerospace and defense sectors as key catalysts for sustained long-term value.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is capturing investor attention following positive Phase 1 data for its subcutaneous Briumvi treatment in Myasthenia Gravis, which the community sees as a significant expansion of the drug's addressable market. Market participants are actively discussing the potential for a major buyout, with long-term investors pointing to strong commercial execution and upcoming clinical milestones as catalysts for a re-rating of the stock.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing high volatility as investors weigh aggressive AI infrastructure spending and data center expansion against concerns regarding the company's debt levels. While community sentiment remains split between bullish expectations for blowout earnings and anxiety over broader sector weakness, many are focused on the stock's potential for a significant reaction following its upcoming earnings report.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is seeing significant investor attention as shares trade near five-year highs following a critical patent extension for its flagship drug Miplyffa through 2041. The community is actively discussing this development alongside multiple analyst price target upgrades, fueling speculation about long-term growth and the potential for a strategic acquisition.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is seeing active community debate as investors weigh strong economic data and the potential for a small-cap breakout against the risk of persistent interest rate pressure. Traders are focused on volatility ahead of upcoming macroeconomic updates, with many actively hedging against a potential correction while others look for signs of a market rotation into smaller-cap names.

Magnite, Inc. provides a technology solution to automate the purchase and sale of digital advertising inventory for buyers and sellers. It features applications and services for digital advertising sellers including websites, mobile applications, and other digital media properties. The company was founded by Frank Addante, Duc Chau, Craig Roah, Julie Mattern and Brian D. Baumgart on April 20, 2007 and is headquartered in New York, NY.

Magnite Inc

Magnite is currently trending as investors look ahead to upcoming earnings while speculating on the impact of potential Google antitrust remedies. The community is actively debating the company's valuation relative to its programmatic CTV growth and the potential for increased share buybacks as a catalyst for price appreciation.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing significant community attention driven by its history as a volatile meme runner and ongoing speculation about a potential short squeeze fueled by a locked-up float. Investors are actively debating the stock's parabolic potential, frequently comparing its share structure and potential for violent upside to other historical high-momentum plays.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

Investors are actively debating the sustainability of the current market rally as broad indices like VOO hit all-time highs amid ongoing geopolitical tensions and uncertainty regarding interest rate policies. The community is heavily focused on balancing long-term index compounding against speculative rotations into AI-linked sectors, with many highlighting the importance of consistency over timing market pullbacks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


jbminn

John Minnihan